A dead hand provision is a clause written into a corporate poison pill that reserves the power to disarm the defense to the directors who were already on the board when the pill was adopted. New directors elected afterward — including a full slate installed through a proxy contest — cannot redeem the rights, so the defense survives even a complete turnover of the board. Delaware and New York courts have struck these provisions down. Georgia’s corporate code expressly permits a version of them. That split is the practical story for anyone trying to figure out whether a dead hand clause will hold.
What the Provision Actually Does
A standard poison pill issues rights to all shareholders that activate when an outside buyer crosses an ownership threshold, typically set between 10 and 20 percent. Once triggered, every shareholder except the acquirer can buy additional stock at a steep discount, diluting the bidder into submission. The sitting board can redeem the rights at any time for a nominal price, which is how friendly deals get through: the board flips the switch off, and the pill goes away.
A dead hand provision rewrites that redemption power. Only “continuing directors” can vote to redeem — meaning directors who were in office when the pill was adopted, plus (in some plans) any new director those incumbents later approve. Directors elected without incumbent blessing become second-class for this one purpose. They can set executive pay, approve budgets, hire officers, and run the business, but they cannot touch the rights plan.
The definition of “continuing director” matters. A narrow version counts only the original directors in office at adoption, so the protected class shrinks as those directors leave. A broader version lets the continuing directors anoint their successors, which perpetuates the incumbent-approved class indefinitely: each newly approved director becomes a continuing director with the power to approve the next one.
Why the Clause Exists
A hostile bidder blocked by a poison pill has one well-worn countermove: run a proxy contest, replace the board, and have the new directors redeem the pill. In a company with a standard pill, that sequence works. The new board takes office, votes to redeem, and the acquisition proceeds.
The dead hand provision is designed to break that sequence. A bidder can win every seat on the board and still find the rights plan intact, because the only people allowed to pull it down are no longer there. The hostile acquirer cannot complete the purchase without triggering the dilution. The shareholders who voted for change find their vote carries real authority over everything except the one question that drove the proxy fight. And the ousted directors retain decisive influence over the deal they were ejected to approve.
That is the mechanism in plain terms. It is also exactly what has made the provision so vulnerable in court.
Delaware: Invalid Under Carmody and Quickturn
Most large public companies are incorporated in Delaware, so Delaware’s view effectively settles the question for a majority of the market. Two 1998 decisions did the settling.
Carmody v. Toll Brothers
The Delaware Court of Chancery took up a dead hand pill directly in Carmody. The court held that the provision created two unequal classes of directors — those with redemption power and those without — based on nothing more than when they joined the board. Delaware law requires any distinction in director authority to appear in the certificate of incorporation. Toll Brothers’ charter did not classify its directors that way, so the dead hand feature had no statutory footing.1Justia Law. Carmody v. Toll Bros., Inc. (1998)
The court also flagged a disenfranchisement problem. If voting in new directors cannot alter the company’s takeover posture, the shareholder franchise becomes an empty exercise on the question that matters most. Annual elections are supposed to let shareholders change the direction of the company; a dead hand pill carves out the biggest decision from that process.
Quickturn Design Systems v. Shapiro
Quickturn’s board tried a workaround. Rather than defend its original dead hand pill, it replaced the clause with a delayed redemption provision that barred any newly elected majority from redeeming the pill for 180 days. The restriction applied equally to all directors, which the board thought would sidestep the two-tier reasoning in Carmody.2Justia Law. Quickturn Design Systems v. Shapiro (1998)
The Delaware Supreme Court rejected that too. It held that the delayed redemption provision violated Section 141(a) of the Delaware General Corporation Law, which requires that the business and affairs of a corporation be managed by or under the direction of its board.3Delaware Code Online. Delaware Code Title 8, Chapter 1, Subchapter IV – Directors and Officers By stripping a newly elected board of redemption authority for six months, the provision “impermissibly circumscribes the board’s statutory power under Section 141(a) and the directors’ ability to fulfill their concomitant fiduciary duties.”2Justia Law. Quickturn Design Systems v. Shapiro (1998)
Taken together, the two cases close the door on both the original dead hand concept and its temporary cousin. Any provision that prevents a duly elected board from exercising full control over a rights plan, whether permanently or for a window of months, conflicts with the statutory framework that gives Delaware boards their power.
New York: Also Invalid
New York got to the same destination by a slightly different route. In Bank of New York Co. v. Irving Bank Corp. (1988), a New York court struck down a continuing-director provision because the New York Business Corporation Law, like Delaware’s, requires any limitation on board authority to appear in the certificate of incorporation. The court also emphasized the discriminatory character of the setup: an incumbent director who won reelection kept redemption power, while a newly elected director chosen in the same vote by the same shareholders did not.4Casemine. Bank of New York Co. v. Irving Bank Corp. (1988)
Georgia: Expressly Permitted by Statute
Georgia is the outlier. Its Business Corporation Code allows a board to set terms for rights and options that limit a new director’s ability to vote for redemption or termination of a rights plan for up to 180 days after the new director’s initial election. The 180-day cap drops away entirely when the restriction is tied to a director’s connection to a hostile bidder, so a director who is an officer, employee, or affiliate of the acquirer can be permanently excluded from redemption votes.5Justia Law. Invacare Corp. v. Healthdyne Technologies, Inc. (1997)
In Invacare Corp. v. Healthdyne Technologies (1997), a federal court applying Georgia law upheld a dead hand poison pill on that statutory basis. The court observed that the “continuing directors” concept is already embedded throughout Georgia’s statutes on business combinations and that the board has broad discretion over the terms of a rights plan. It distinguished Georgia from Delaware and New York by noting that Georgia’s code lacks any express limitation on board authority over rights plans comparable to what those states’ courts had identified.5Justia Law. Invacare Corp. v. Healthdyne Technologies, Inc. (1997)
The practical consequence is simple. State of incorporation determines whether a dead hand clause has any chance of surviving a challenge. A Delaware or New York company adopting one is adopting a provision that case law has already invalidated. A Georgia company has explicit statutory backing.
The Fiduciary Doctrines That Make It Hard to Defend
Even where the provision is not categorically barred, directors who adopt takeover defenses face fiduciary standards that require them to justify what they did rather than receive automatic deference.
Under the Unocal test from the 1986 Delaware Supreme Court decision in Unocal Corp. v. Mesa Petroleum, directors must first show they had reasonable grounds for believing a threat existed, then show that the defensive response was proportional to that threat. A dead hand provision is a poor fit for proportionality: it does not respond to a particular bid but preemptively strips future boards of authority regardless of what offer later appears.
The Blasius doctrine applies a tougher standard when a board action primarily aims to interfere with shareholder voting power. Directors who impair the effectiveness of a shareholder vote, even in good faith, must show a “compelling justification.” A dead hand clause is almost a textbook trigger, because its entire function is to ensure shareholders cannot use their votes to change the company’s defensive posture.
Personal Liability Risk for the Board
Delaware’s exculpation statute lets a company shield directors from monetary damages for duty-of-care breaches, but the protection has hard limits. It does not cover breaches of the duty of loyalty, acts in bad faith, intentional misconduct, or knowing violations of law.6Delaware Code Online. Delaware Code Title 8, Chapter 1, Subchapter I – Formation
Adopting a provision that existing case law has clearly invalidated can look less like a misjudgment and more like a knowing violation, especially if the record suggests the motive was entrenchment rather than genuine corporate protection. If a court frames the adoption as bad faith, charter-based liability limits fall away and the corporation cannot indemnify the directors for the resulting judgment. That exposure, more than the invalidity itself, is what keeps most corporate counsel from recommending a dead hand pill for a Delaware company.
Proxy Advisor Response
Even where the provision might legally survive, it draws fire from the institutional investors who hold most public company shares. Institutional Shareholder Services recommends voting against or withholding support from every incumbent director nominee at any company whose poison pill contains a dead hand or slow hand feature. The policy applies to meetings on or after February 1, 2026.7Institutional Shareholder Services. United States Proxy Voting Guidelines
Glass Lewis is similarly hostile to shareholder rights plans generally. Its 2026 benchmark policy recommends in favor of shareholder proposals that would require shareholder approval of any future poison pills and the redemption of pills adopted without shareholder input.8Glass Lewis. 2026 Benchmark Policy Guidelines – Shareholder Proposals Because institutional investors generally follow those recommendations, a board that adopts a dead hand provision can lose its own seats at the next annual meeting. That is an awkward outcome for a defense designed to protect incumbents.
A Different Instrument With a Similar Name
One point of confusion worth clearing up: a “dead hand proxy put” is not a poison pill feature. It is a clause in a corporate loan agreement that lets the lender accelerate the debt if a majority of the board becomes composed of “non-continuing directors” within a short period, often one or two years. The dead hand feature in these clauses classifies any director elected as a result of an actual or threatened proxy contest as a non-continuing director, which can trigger a default.
The purpose is different. The lender is protecting its credit risk, not the incumbent board’s seats. But the effect on a hostile bidder resembles a poison pill: a successful proxy contest can trigger billions in accelerated debt and make the deal far more expensive. Unlike dead hand pills, dead hand proxy puts have not been categorically invalidated in Delaware, because they arise from negotiated contracts with third-party lenders rather than from unilateral board action. They still draw criticism from courts and governance advocates who view them as backdoor entrenchment.
Where That Leaves a Dead Hand Clause Today
For a company incorporated in Delaware or New York, a dead hand provision is a defense that case law has already taken off the table, with personal liability risk layered on top. For a company incorporated in Georgia, the statute gives the clause explicit cover, and at least one federal decision has enforced it. For almost every other state, the Delaware reasoning in Carmody and Quickturn is persuasive authority that courts will likely follow, though no categorical rule exists until the question is tested locally. And regardless of where the company is incorporated, the two major proxy advisors will treat the clause as grounds to recommend against the directors who adopted it.